# Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

> **NCT00564889** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 35 (actual)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00564889
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-02
- **Final completion:** 2012-06
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2013-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00564889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00564889, "Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00564889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*